Groundbreaking Insights into Life Sciences Innovation
Uncover the pioneering solutions and market trends of Take Solutions, a key player in clinical services and regulatory affairs. Explore opportunities in the pharmaceutical industry, future projections, and associated risks for informed decision-making and strategic planning.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. Download presentation by click this link. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
E N D
Presentation Transcript
Starters Shriram Group founded enterprise Promoters own 63.14% Market cap of Rs. 1865 cr Employee strength 1500 Team comprises R&D experts, doctors and life sciences experts Some brands Navitas LS IP Ecron Acunova A specialised provider of clinical services to biosimilars and regenerative medicine Intelent LS big data Take supply chain and Take-Towel Solutions SCM solutions pharmaReady Its a documentation management and e- submission product suite
Market Clinical Regulatory Safety Big Pharma Small & Medium Generics Biosimilars Total current market size $12bn $5bn $5.3bn Take provides data integration (integrates data irrespective of the brand of system) and advanced analytics. They prepare a dashboard to track and source data
On The Ground Facts 1) In the area of source data verification 50% of the time spent at clinical research site on SDV is for a 2.7% data correction rate. Research heads travel thousands of miles to read transcripts for their site monitoring accountability. 30% of R&D budget goes into site monitoring Only 10% of trials complete on time 2) Projected RoI on Pharmaceutical R&D has reduced from 10% before 2010 to 4% currently due to rise in asset development cost.
Opportunities Europe is mandating use of IDMP by 2018. The standard defines hundreds of attributes per product and includes data that is typically owned by multiple departments, not just regulatory affairs. Other regions are expected to follow. Drugs worth $200bn slated to go off patent in the next 3 years; Biologics worth $60bn going off patent in the next few years More emerging markets adopting regulatory framework in lifescience and pharmaceuticals Take has accomplished more than 2,00,000 regulatory filings. They did 7000 filings for a globally leading pharma company with a 100% hit rate.
Numbers CAGR growth 12% Metric FY 13-14 FY 14-15 FY 15-16 Net Sales 816 730 1030 Op profit OPM (%) 71 8.7 90 12.3 139 13.5 40% Net profit NPM (%) 58 7.1 70 9.6 120 11.7 44% Mcap/sales 1.8 Mcap/EBITDA Mcap/net profit Take Solutions Quintiles IMS 8 15 2.4 10.4 23
Risks Debtor days = 100 days Execution risks due to shortage of skilled manpower Stronger rupee
